|
|
 |
|
Viewing report
|
|
|
|
Exploring New Opportunities in the Expanding Diabetes Market: Novel Targets and Strategies
Decision Resources, Inc, Feb 2011, Pages: 42
The expanding diabetes market is opening up new and lucrative opportunities for companies with innovative technologies and experimental candidates. The launch of novel agents and a steady increase in the drug-treated patient population are fueling growth in this market. The R&D pipeline includes drugs against the promising novel targets SGLT, PTP1B, 11ß-HSD1, and others; clinical trials testing disease-modifying agents for type 1 diabetes are also under way.
Questions answered in this report:
- Type 2 diabetes is a significant public health threat and an important and growing pharmaceutical market; type 1 diabetes also continues to suffer from significant unmet needs. How large is the current market for type 1 and type 2 diabetes? How much will this market grow over the next ten years? What factors will drive this market growth?
- Unmet needs in type 2 diabetes have led to a flurry of R&D activity and a dense development pipeline. What novel diabetes targets hold the most promise for drug discovery and development? Which new treatment strategies are being pursued, and which are the most advanced?
- The need for disease-modifying therapies, especially for type 1 diabetes, has prompted the clinical development of several novel technologies. What novel approaches are in clinical development for type 1 diabetes? Which companies are leading the development of these programs?
- The current market landscape offers significant commercial opportunity to innovative biotech companies with novel development programs. Which biotech companies have developed innovative approaches to drug discovery and development? How far have these programs advanced?
- Pharmaceutical companies can refuel pipelines and access new technologies through partnerships and M&As. Which pharmaceutical companies have formed major alliances with biotech companies? Which therapeutic strategies are drawing the interest of Big Pharma?
- Eli Lilly and Boehringer Ingelheim formed a high-value deal in January 2011 for the development of new diabetes therapies. What are the key features of this deal? How does this collaboration address each partner’s strategic interests? How does this deal reflect trends in diabetes partnering activity?
Scope of the report:
- Introduction to the diabetes market: Market size, market growth, market drivers, product sales, unmet needs.
- Disease and therapy: Disease etiology and pathophysiology, current therapies, mechanisms of action, DPP-IV inhibitors, GLP-1 analogues, PPAR-g agonists.
- Primary data: Survey of 50 U.S. endocrinologists and 50 U.S. primary care physicians ranking the top unmet needs in diabetes.
- Novel targets for type 2 diabetes: Mechanisms of action, novel targets and approaches, compounds in development, companies, and partnerships.
- Novel approaches to insulin delivery and disease modification: Inhaled insulin, buccal delivery, anti-CD3 MAbs, immunotherapies, preservation of beta-cell mass and function, vaccines, islet-cell neogenesis.
- Dealmaking activity: Corporate partnerships, M&As, innovative biotech companies.
|
|
|
|
